Navigation Links
Radient Pharmaceuticals Corporation Expands Distribution of Onko-Sure® in Asia; Receives Payment on First Order of 60 Kits

TUSTIN, Calif., Dec. 21, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC.PK - News) (OTCPK:RXPC.PK - News), a developer and marketer of cancer tests, today announces it has expanded its distribution agreement with UniPharma Taiwan headquartered in Taipei, Taiwan.

Previously, Radient's agreement with Uni Pharma provided UniPharma the exclusive right to distribute Radient's flagship product Onko-Sure® cancer test in Taiwan.  Radient and UniPharma have now expanded the territory to include Singapore, Hong Kong and Macau.  As a full-service distribution partner, UniPharma handles regulatory approvals in assigned territories. Onko-Sure® is a non-invasive in vitro diagnostic blood biomarker test for cancer.

Uni Pharma will be receiving its first shipment of test kits this month, December 2011.

With a combined population of over 35 million people, Taiwan, Singapore, Hong Kong, and Macau is a significant health care market.  Cancer remains the leading cause of death in Taiwan, according to the latest statistics released by the Taiwan Department of Health on June 15, 2011 (Taiwan Today, June 16 2011).  The most prevalent types of cancer are lung cancer, liver cancer and colorectal cancer, the three of which were responsible for over half of all cancer deaths in Taiwan.

"Onko-Sure® is a cost effective, high value In Vitro Diagnostic cancer test that should be included as a valuable diagnostic tool by doctors, clinicians, and other oncology healthcare professionals," stated Terry Lin, General Manager of UniPharma.  "The UniPharma team is excited to distribute Onko-Sure® in our assigned territories of Taiwan and now Singapore, Hong Kong, and Macau.  UniPharma has increased its medical sales team and committed to present at upcoming regional cancer conferences to increase awareness of Onko-Sure®. UniPharma has already launched its first Onko-Sure outreach campaign with a booth at the Taiwan Colorectal Cancer Conference at the Taiwan International Convention Center (December 9-11) in Taipei."

"Radient welcomes UniPharma's increased commitment to Onko-Sure®," said the Company's Chairman and CEO, Douglas MacLellan.  "We look forward to a continued, successful working relationship as UniPharma advocates the use of Onko-Sure in these important health care markets."

About UniPharma Taiwan:

Founded in 1998, UniPharma was established by a group of professional managers with multi-national pharmaceutical company backgrounds and extensive experience in the pharmaceutical industry.  Uni Pharma is dedicated to supplying the best products to patients and delivering the most value to its partners.  Uni Pharma distributes pharmaceutical and medical device products in Taiwan for nine international firms from seven countries across the globe.  For more information, visit

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. Diagnostics are the key to informed treatment decisions; identifying the right treatment for the right patient can make all the difference, particularly in cancer patients.  To learn more about our company, products, and potentially life-saving cancer test, visit

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

For additional information on Radient Pharmaceuticals Corporation and its products visit: or or e-mail  For Investor Relations contact Paul Knopick at: or 949-707-5365.

SOURCE Radient Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
2. Radient Pharmaceuticals Corporation Joins OTCQX
3. Merriman Capital Announces Sponsorship of Radient Pharmaceuticals Corporation on OTCQX
4. Radient Pharmaceuticals Announces FY 2011 Third Quarter Results
5. Radient Pharmaceuticals Asks DHS Holding Co. to Retract News Release Saying It Will Enter Into Talks With Radient Pharmaceuticals Corporation
6. Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital
7. Radient Pharmaceuticals Corporation Receives $500,000 in New Capital
8. Radient Pharmaceuticals Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation
9. Radient Pharmaceuticals Submits an Abstract to the American Society of Colon and Rectal Surgeons
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... WASHINGTON , Nov. 25, 2015  The ... Obstetricians and Gynecologists (ACOG), and the March of ... bipartisan Protecting Our Infants Act of 2015 ... the number of newborns born exposed to drugs, ... Since the bill,s introduction, all three organizations have ...
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
Breaking Medicine Technology:
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 , ... ... Thanksgiving through Christmas Eve on several models of traditional and far-infrared saunas. ... . Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, ... again for its stellar workplace culture with the company’s Cincinnati office being named ... Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual ...
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dr. John ... to learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. ... solution for thicker and fuller hair, without the need for surgery, prescription pills, or ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and UN ... African Centres of Excellence, and public R&D institutions, civil societies and other partners ... the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The ...
Breaking Medicine News(10 mins):